Biotech Revenue Projections Clouded by Medicaid Enrollment Losses from Trump-Era Tax Law

Experts warn that a tax and spend law passed under the Trump administration could reduce Medicaid enrollment, making it harder for biotech companies to secure funding and recruit patients for clinical trials. The insurance coverage losses are expected to dampen revenue projections for the industry, according to a report by Fierce Biotech.

The law’s impact on Medicaid enrollment creates new headwinds for drug developers. Smaller patient pools complicate trial recruitment, while investor confidence may decline if market access shrinks. Experts cited in the report said the changes could make fundraising more difficult for biotechs.

The warning highlights a downstream effect of fiscal policy on life sciences. Biotech companies depend on large, insured patient populations to run trials and generate reliable revenue forecasts. When fewer people have coverage, the addressable market for new therapies narrows, potentially delaying drug development and raising costs. The effect could be especially pronounced for treatments aimed at chronic or costly conditions that rely on Medicaid as a primary payer.

Source: original report